5-bromo-2-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridine | 784149-29-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-bromo-2-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridine
• 英文别名: 4-[2-(5-bromopyridin-2-yl)oxyethyl]-5-methyl-2-phenyl-1,3-oxazole
• CAS: 784149-29-7
• 化学式: C₁₇H₁₅BrN₂O₂
• 分子量: 359.222
• InChiKey: OYDIZDANAPMKDS-UHFFFAOYSA-N

物化性质

• 沸点：
  486.0±55.0 °C(Predicted)
• 密度：
  1.394±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  48.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-bromo-2-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridine 在 sodium tetrahydroborate 、 正丁基锂 、 草酰氯 、 sodium iodide 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 9.0h， 生成 5-(iodomethyl)-2-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridine
  参考文献：
  名称：

  Pyridine-3-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents

  摘要：

  A series of novel pyridine-3-propanoic acids was synthesized. A structure-activity relationship study of these compounds led to the identification of potent dual PPARalpha/gamma agonists with varied isoform selectivity. Based on the results of efficacy studies in diabetic (db/db) mice, and the desired pharmacokinetic parameters, compounds (S)-14 and (S)-19 were selected for further profiling.

  DOI：

  10.1016/j.bmcl.2006.08.110
• 作为产物：
  描述：

  2,5-二溴吡啶 、 2-(5-甲基-2-苯基-1,3-恶唑-4-基)-1-乙醇 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以83%的产率得到5-bromo-2-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridine
  参考文献：
  名称：

  [EN] ALPHA SUBSTITUTED CARBOXYLIC ACID AS PPAR MODULATORS
  [FR] ACIDES CARBOXYLIQUES ALPHA-SUBSTITUES COMME MODULATEURS DU RECEPTEUR ACTIVE PAR LES PROLIFERATEURS DE PEROXYSOME (PPAR)

  摘要：

  式(I)的α-取代羧酸，其中R'和R2如规范中定义，R3为A)式(II)；B)式(III)；C)式(IV)；和D)式(V)；其中Y、Art、Are、AP、R4、R5、R6、R7、R6、R9、R9a、R10、R'、R12、R17、环A和p如规范中定义；含有所述化合物或其盐的有效量的药物组合物对于治疗PPAR，特别是PPAR α/y相关的疾病，如糖尿病、血脂异常、肥胖和炎症性疾病是有用的。

  公开号：

  WO2004092145A1

文献信息

• Alpha substituted carboxylic acids
  申请人：Su Guo Wei

  公开号：US20050187266A1

  公开（公告）日：2005-08-25

  Alpha substituted carboxylic acids of formula (I): wherein R 1 and R 2 are as defined in the specification and R 3 is wherein Y, Ar 1 , Ar 2 , Ar 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 9a , R 10 , R 11 , R 12 , R 17 , ring A, and p are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR, specifically PPAR α/γ related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.

  式(I)的α取代羧酸，其中R1和R2如规范中定义，R3为，其中Y、Ar1、Ar2、Ar3、R4、R5、R6、R7、R8、R9、R9a、R10、R11、R12、R17、环A和p如规范中定义；含有所述化合物或其盐的有效量的药物组合物对于治疗PPAR，特别是PPAR α/γ相关疾病，如糖尿病、血脂异常、肥胖和炎症性疾病是有用的。
• EP1615899A1
  申请人：——

  公开号：EP1615899A1

  公开（公告）日：2006-01-18
• [EN] ALPHA SUBSTITUTED CARBOXYLIC ACID AS PPAR MODULATORS<br/>[FR] ACIDES CARBOXYLIQUES ALPHA-SUBSTITUES COMME MODULATEURS DU RECEPTEUR ACTIVE PAR LES PROLIFERATEURS DE PEROXYSOME (PPAR)
  申请人：PFIZER

  公开号：WO2004092145A1

  公开（公告）日：2004-10-28

  Alpha substituted carboxylic acids of formula (I): wherein R' and R2 are as defined in the specification and R3 is A) formula (II); B) formula (III); C) formula (IV); and D) formula (V); wherein Y, Art, Are, AP, R4, R5, R6, R7, R6, R9, R9a, R10, R', R12, R17, ring A, and p are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR, specifically PPAR α/y related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.

  式(I)的α-取代羧酸，其中R'和R2如规范中定义，R3为A)式(II)；B)式(III)；C)式(IV)；和D)式(V)；其中Y、Art、Are、AP、R4、R5、R6、R7、R6、R9、R9a、R10、R'、R12、R17、环A和p如规范中定义；含有所述化合物或其盐的有效量的药物组合物对于治疗PPAR，特别是PPAR α/y相关的疾病，如糖尿病、血脂异常、肥胖和炎症性疾病是有用的。
• Pyridine-3-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents
  作者：Paul S. Humphries、Simon Bailey、Jonathon V. Almaden、Sandra J. Barnum、Thomas J. Carlson、Lance C. Christie、Quyen-Quyen T. Do、James D. Fraser、Mary Hess、Jack Kellum、Young H. Kim、Guy A. McClellan、Kathleen M. Ogilvie、Brett H. Simmons、Donald Skalitzky、Shaoxian Sun、David Wilhite、Luke R. Zehnder

  DOI：10.1016/j.bmcl.2006.08.110

  日期：2006.12

  A series of novel pyridine-3-propanoic acids was synthesized. A structure-activity relationship study of these compounds led to the identification of potent dual PPARalpha/gamma agonists with varied isoform selectivity. Based on the results of efficacy studies in diabetic (db/db) mice, and the desired pharmacokinetic parameters, compounds (S)-14 and (S)-19 were selected for further profiling.